A huge victory for Finnegan Henderson on their PTAB win on behalf of Incyte Corp. in hair loss treatment patent challenge

DEG worked closely with Finnegan Henderson on this matter and in a final inter partes review decision the Patent Trial and Appeal Board granted Incyte Corp. a victory by ruling Concept Pharmaceuticals Inc.’s patent relating to a potential hair loss treatment was unpatentable. Concert owns a patent with claims covering CTP-543 – a chemical compound being evaluated for the treatment of hair loss. Incyte filed an IPR petition challenging Concert’s patent on anticipation and obviousness grounds and ultimately prevailed when the PTAB declared the patent invalid because it covers chemical compounds that would have been obvious.

PTAB Axes Hair Loss Treatment Patent In Incyte Challenge – Law360